Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

COVID-19 outcomes no worse in patients on TNF inhibitors or methotrexate

Key clinical point: Results of a cohort study provide additional evidence that continued use of tumor necrosis factor inhibitors or methotrexate is acceptable in most patients who acquire COVID-19.

Major finding: The likelihood of hospitalization or death was not statistically different between COVID-19 patients exposed or not exposed to those drugs, with risk ratios of 0.91 and 0.87, respectively.

Study details: A study of a global research network database including 32,076 patients with COVID-19, including 214 with recent exposure to tumor necrosis factor inhibitors or methotrexate.

Disclosures: Authors reported no conflicts of interest and no funding sources related to the study.


Zinn Z et al. J Am Acad Dermatol. 2020 Sep 11. doi: 10.1016/j.jaad.2020.09.009.